Barnes G - Search Results

1

Tislelizumab versus chemotherapy as second-line treatment for European and North American patients with advanced or metastatic esophageal squamous cell carcinoma: a subgroup analysis of the randomized phase III RATIONALE-302 study.

Ajani J, El Hajbi F, Cunningham D, Alsina M, Thuss-Patience P, Scagliotti GV, Van den Eynde M, Kim SB, Kato K, Shen L, Li L, Ding N, Shi J, Barnes G, Van Cutsem E. Ajani J, et al. Among authors: barnes g. ESMO Open. 2024 Jan;9(1):102202. doi: 10.1016/j.esmoop.2023.102202. Epub 2023 Dec 19. ESMO Open. 2024. PMID: 38118368 Free PMC article. Clinical Trial.

2

Tislelizumab versus chemotherapy as second-line treatment of advanced or metastatic esophageal squamous cell carcinoma (RATIONALE 302): impact on health-related quality of life.

Van Cutsem E, Kato K, Ajani J, Shen L, Xia T, Ding N, Zhan L, Barnes G, Kim SB. Van Cutsem E, et al. Among authors: barnes g. ESMO Open. 2022 Aug;7(4):100517. doi: 10.1016/j.esmoop.2022.100517. Epub 2022 Jul 1. ESMO Open. 2022. PMID: 35785595 Free PMC article. Clinical Trial.

3

Second-line tislelizumab versus chemotherapy in Japanese patients with advanced or metastatic esophageal squamous cell carcinoma: subgroup analysis from RATIONALE-302.

Hara H, Satoh T, Kojima T, Tsushima T, Sunakawa Y, Okada M, Ding N, Wu H, Li L, Yu T, Barnes G, Kato K. Hara H, et al. Among authors: barnes g. Esophagus. 2024 Apr;21(2):102-110. doi: 10.1007/s10388-023-01040-w. Epub 2024 Jan 19. Esophagus. 2024. PMID: 38240916 Free PMC article.

4

The effects of tislelizumab plus chemotherapy as first-line treatment on health-related quality of life of patients with advanced squamous non-small cell lung cancer: Results from a phase 3 randomized clinical trial.

Wang J, Yu X, Barnes G, Leaw S, Bao Y, Tang B. Wang J, et al. Among authors: barnes g. Cancer Treat Res Commun. 2022;30:100501. doi: 10.1016/j.ctarc.2021.100501. Epub 2021 Dec 17. Cancer Treat Res Commun. 2022. PMID: 34952253 Free article.

5

The effects of tislelizumab treatment on the health-related quality of life of patients with advanced non-small cell lung cancer.

Huang D, Zhou C, Barnes G, Ma Y, Li S, Zhan L, Tang B. Huang D, et al. Among authors: barnes g. Cancer Med. 2023 Aug;12(16):17403-17412. doi: 10.1002/cam4.6361. Epub 2023 Aug 17. Cancer Med. 2023. PMID: 37587845 Free PMC article. Clinical Trial.

6

Examining the Impact of Tislelizumab Added to Chemotherapy on Health-Related Quality-of-Life Outcomes in Previously Untreated Patients With Nonsquamous Non-Small Cell Lung Cancer.

Lu S, Yu Y, Barnes G, Qiu X, Bao Y, Tang B. Lu S, et al. Among authors: barnes g. Cancer J. 2022 Mar-Apr 01;28(2):96-104. doi: 10.1097/PPO.0000000000000583. Cancer J. 2022. PMID: 35333492 Free PMC article. Clinical Trial.

7

Real-World longitudinal practice patterns in the use of PD-1 and PD-L1 inhibitors as First-Line therapy in patients with Non-Small cell lung cancer in the United States.

Veluswamy R, Hirsch FR, Taioli E, Wisnivesky J, Strauss R, Harrough D, Tang B, Barnes G. Veluswamy R, et al. Among authors: barnes g. Cancer Med. 2022 Nov;11(22):4265-4272. doi: 10.1002/cam4.4785. Epub 2022 May 2. Cancer Med. 2022. PMID: 35499294 Free PMC article.

8

Effects of tislelizumab on health-related quality of life in patients with recurrent or metastatic nasopharyngeal cancer.

Yang Y, Pan J, Chen N, Guo Y, Huang X, Wu Y, Leaw S, Bai F, Wang Y, Zhao N, Tang B, Barnes G. Yang Y, et al. Among authors: barnes g. Head Neck. 2024 Sep;46(9):2301-2314. doi: 10.1002/hed.27785. Epub 2024 Apr 26. Head Neck. 2024. PMID: 38671587 Clinical Trial.

9

Use of PD-1 and PD-L1 inhibitors after first-line therapy in esophageal cancer patients in the US.

Allaire JC, Balk M, Azmi S, Handl HL, Yang K, Barnes G. Allaire JC, et al. Among authors: barnes g. Curr Med Res Opin. 2021 Aug;37(8):1403-1407. doi: 10.1080/03007995.2021.1929134. Epub 2021 Jun 3. Curr Med Res Opin. 2021. PMID: 33989092

10

An observational, multicentre study of cabazitaxel in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (CAPRISTANA).

Carles J, Pichler A, Korunkova H, Tomova A, Ghosn M, El Karak F, Makdessi J, Koroleva I, Barnes G, Bury D, Özatilgan A, Hitier S, Katolicka J. Carles J, et al. Among authors: barnes g. BJU Int. 2019 Mar;123(3):456-464. doi: 10.1111/bju.14509. Epub 2018 Sep 16. BJU Int. 2019. PMID: 30098093 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,495 results

Search Page

Filters